Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study

Sharma, Surendra Kumar; Almustafa, M.; Oh, Seungbae; Azar, Sami T.; Shestakova, Marina Vladimirovna; Güler, Serdar; Vaz, J. A.

doi:10.1185/030079908x260952

Cited by 23 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it is always necessary to exercise care when adjusting the insulin dose, and to pay attention to possible interactions with coadministered drugs, the characteristics of BIAsp 30 suggest that it may be possible to increase the dose slightly, and reduce HbA1c levels further without increasing the incidence of hypoglycemic episodes. Since several previous studies [13][14][15][16][17][18] , some of them were conducted in Japanese patients, have shown that BIAsp 30 improved HbA1c/daily glycemic profiles equally versus multiple insulin injection therapy or better than previous OAD therapy in insulinnaïve patients. Hypoglycemic episodes were not increased versus these regimens.…”

Section: Discussionmentioning

confidence: 99%

Step-up therapy with biphasic insulin aspart-70/30—Sapporo 1-2-3 study

Yoshioka¹,

Kurihara²,

Manda³

et al. 2009

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

The effectiveness of BIAsp 30 step-up therapy in achieving glycemic control in Japanese patients with type 2 diabetes mellitus was investigated. Study subjects were 99 patients with type 2 diabetes mellitus aged over 20 years who were judged to require insulin therapy due to poor glucose control (HbA1c level of ≥7.5%). BIAsp 30 dosage was determined by the patient's attending physician; co administration of hypotensive agents and antilipemic agents was permitted, but OAD co administration was limited to patients already receiving such drugs at the start of the study. Patients who did not achieve HbA1c <6.5% after 16±5 weeks with QD (Phase 1) were stepped up to BID (Phase 2). If patients still had not achieved HbA1c <6.5% after 16±5 weeks with BID, they were stepped up to TID (Phase 3). 55 of the 99 enrolled subjects completed the study and the rates of achievement of HbA1c<6.5% and HbA1c<7.0% were 45.5% and 74.5% respectively. Of all registered subjects, 5.1% (5/99) achieved HbA1c<6.5% in QD, 19.5% (16/82) in BID, and 20.6% (7/34) in TID. Statistically significant reductions in HbA1c levels were recorded at the conclusion of each phase, with no incidents requiring intervention, indicating that BIAsp 30 step-up therapy is a safe, simple therapy that can be useful in achieving better glycemic control for Japanese patients with type 2 diabetes mellitus.

show abstract

Section: Discussionmentioning

confidence: 99%

Step-up therapy with biphasic insulin aspart-70/30—Sapporo 1-2-3 study

Yoshioka¹,

Kurihara²,

Manda³

et al. 2009

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…However, intensive insulin therapy whilst improving glycemic control is associated with increased risk of hypoglycemia leading to significant morbidity and mortality. 20 Hypoglycemia may have particularly serious outcomes in elderly or frail people with type 2 diabetes. The incidence for severe hypoglycemia has been reported to be 11.8 and 0.9 events per 100 patient-years for patients with type 2 diabetes treated with insulin and sulfonylureas respectively.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Insulin Detemir Among Adult Filipino Patients with Type 2 Diabetes: The Philippine Cohort of the Global A1chieve Study

Sy¹,

Mirasol

Pasaporte³

et al. 2013

JAFES

View full text Add to dashboard Cite

Objective. To present the results from the Philippine cohort of the A1chieve study receiving insulin detemir (IDet) ± oral antidiabetic drugs.Methodology. A1chieve is a multinational, 6-month, observational study of 66,726 people with type 2 diabetes mellitus (T2DM), both insulin users and non-insulin users, started on IDet, insulin aspart or biphasic insulin aspart in 28 countries across four continents. This subgroup analysis evaluates the safety and effectiveness of IDet in 988 subjects from the Philippines.Results. At baseline the mean age, duration of diabetes and mean BMI were found to be 57±11.9 yrs, 6.9±5.3 yrs and 26±4.8 kg/m 2 respectively. Majority of subjects were insulin-naive (84.3%) and glycemic control was poor in all the groups at baseline. At the end of 24 weeks, there were significant improvements following IDet initiation with a 2.1% reduction in mean HbA1c. The HbA1c target of <7% was achieved by 46.8% subjects at the study end. Although not statistically significant, there was a modest decrease in body weight in all the groups. There was no increase in the incidence of hypoglycemia among baseline insulin-naive subjects, while a significant reduction in hypoglycemia was seen among prior insulin users.Conclusions. IDet appears to be an effective and safe option for individuals with T2DM in the Philippines. HbA1C was lowered to target, and there was no increase in incidence of hypoglycemia and body weight with IDet.

show abstract

“…They provide peaks of plasma insulin aspart to control postprandial blood glucose (PPBG) levels, as well as a steady flow of basal, protaminated insulin to maintain glucose control between meals. In a large observational study of patients with type 2 diabetes, BIAsp 30 has shown greater improvements in glycaemic control in insulin-naïve patients than in patients previously treated with insulin 11 . Furthermore, HbA 1c targets were reached with a lower dose of BIAsp 30 compared with insulin pre-treated patients.…”

Section: Introductionmentioning

confidence: 95%

Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study

Yang

Benroubi

Borzı̀

et al. 2009

Current Medical Research and Opinion

View full text Add to dashboard Cite

This open-label, non-randomised, observational study demonstrated that initiating insulin therapy with BIAsp 30 significantly improved glycaemic control in insulin-naïve patients previously poorly controlled on OADs. The rate of major hypoglycaemia was reduced and treatment satisfaction increased after initiation of BIAsp 30. Furthermore, better glycaemic control was achieved with BIAsp 30 without OAD compared to with OAD.

show abstract

Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study

Abstract: According to this observational study, in clinical practice, initiating or transferring uncontrolled patients to biphasic insulin aspart improved glycaemic control without using a strict insulin algorithm.

Cited by 23 publications

References 11 publications

Step-up therapy with biphasic insulin aspart-70/30—Sapporo 1-2-3 study

Step-up therapy with biphasic insulin aspart-70/30—Sapporo 1-2-3 study

Safety and Efficacy of Insulin Detemir Among Adult Filipino Patients with Type 2 Diabetes: The Philippine Cohort of the Global A1chieve Study

Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study

Contact Info

Product

Resources

About